HPGC Renmintongtai Pharmaceutical Corp

Renmintongtai announced on September 29 that the company has received the first-instance judgment in the second retrial of its construction contract dispute with Heilongjiang No.7 Construction Engineering Co., Ltd. from the Harbin Intermediate People's Court. The court confirmed that the Construction Contract, Supplementary Agreement, and other related documents signed by both parties are invalid, ordered Heilongjiang No.7 Construction to return overpaid project funds of approximately 55.18 million yuan to the company, withdraw from the project construction site, hand over the construction in progress and the construction site to the company, and also transfer project-related materials. The dispute originated from the Sanjing Women's Hospital complex building project in 2008. In 2009, the two parties signed the Supplementary Agreement for the Sanjing Women's Specialist Hospital Complex Building Project, but the company failed to submit the project to the board of directors for review at the outset. In 2010, an administrative law enforcement department ordered the project to stop work. After that, the two parties failed to reach an agreement through multiple negotiations. In 2014, Heilongjiang No.7 Construction filed a lawsuit with the intermediate court, demanding that the company pay project progress payments of 30 million yuan. The original first-instance and second-instance judgments ordered the company to pay project payments and related expenses of approximately 32.55 million yuan, which have already been fully executed. After retrial and remand for a new trial, this is the first-instance judgment in the second retrial. In the first half of 2026, Renmintongtai achieved revenue of 5.408 billion yuan and net profit attributable to the parent company of 81 million yuan.

Renmin Tongtai has released its 2026 interim report, with net profit attributable to the parent company at 81.0014 million yuan, an increase of 11.60% compared to the same period last year. The company's total operating revenue was 5.408 billion yuan, up 5.03% year-on-year, marking two consecutive years of growth. Net cash outflow from operating activities was 418 million yuan, the asset-liability ratio fell to 56.55%, gross margin edged up to 8.11%, and ROE stood at 2.62%.